An anonymous director reports

CLEARMIND MEDICINE AND SCISPARC REFLECT ON SUCCESSFUL COLLABORATION IN 2023 AIMING TO UPGRADE WIDE RANGE OF PSYCHEDELIC- BASED TREATMENTS

Clearmind Medicine Inc. is reflecting on the successful collaboration with SciSparc Ltd. in 2023. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office for unique combinations of future psychedelic-based compounds. The patent applications were filed as part of Clearmind's continuing collaboration with SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

The patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine and ketamine, each with palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide.

The patent applications are part of the company's commitment to offer patients safer and more effective treatments than those available today partly by strengthening its intellectual property portfolio to broaden the therapeutic psychedelic tool box for patients with mental health disorders that require transformative medicines, and developing treatments that offer synergy, efficacy and safety while reducing cost.

Clearmind has a broad IP footprint in the psychedelic space, with 51 patents in 15 utility patent families, of which 26 are granted patents in major jurisdictions like the U.S., Europe, China and India and 25 patent-pending applications internationally.

As part of the collaboration agreement between Clearmind and SciSparc, originally announced on March 8, 2022, any assets generated from the collaboration shall be jointly owned by Clearmind and SciSparc.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company's intellectual portfolio currently consists of 15 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol CMND and on the Frankfurt Stock Exchange under the symbol CWY.

We seek Safe Harbor.